Freshpet Q2 net sales up 25.6% to $183.3M; raises FY adjusted EBITDA guide to at least $55M

Freshpet, Inc.

2023-Q2 EPS reported -$0.87 revenue$350,853,000

Net sales $183.3M (+25.6% YoY); net loss narrowed to $17.0M from $20.6M.
Adjusted EBITDA improved to $9.0M from ($1.9M) in prior year quarter.
Raises full-year 2023 adjusted EBITDA guidance to at least $55M from $50M.
Reaffirms net sales guidance of ~$750M (26% YoY growth) and capex of ~$240M.
Volume growth accelerating; strong performance on input costs, logistics, and quality.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Freshpet, Inc. reported second quarter ended June 30, 2023 results: revenue Net sales of $183.3 million, net income Net loss of $17.0 million. Guidance raised.

Period: second quarter ended June 30, 2023
Revenue: Net sales of $183.3 million
Net income: Net loss of $17.0 million
Guidance: raised
Result: reported results

Exact text from the filing

Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its second quarter ended June 30, 2023 . Second Quarter 2023 Financial Highlights Compared to Prior Year Period ● Net sales of $183.3 million, an increase of 25.6% ● Net loss of $17.0 million, compared with prior year net loss of $20.6 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Freshpet, Inc. updated its Full Year 2023 guidance (raised).

Period: Full Year 2023
Guidance: raised
Result: guidance update

Exact text from the filing

Raises Adjusted EBITDA guidance; re-affirms net sales guidance

View on SEC.gov

Browse all earnings releases →

Freshpet, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-022194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.